One Case of Severe Diarrhea Caused by Semaglutide Injection

doi:10.19803/j.1672-8629.20240655

Abstract

Abstract: Objective To analyze one case of severe diarrhea induced by semaglutide injection and to provide clinical physicians with references for its rational use. Methods Based on findings of research currently available, the diagnostic and therapeutic process, risk factors, potential mechanisms and treatment strategies related to a patient with severe diarrhea that was considered to have been caused by semaglutide injection were analyzed. Results During hospitalization, the patient experienced severe diarrhea after receiving two doses of semaglutide injection (0.5 mg). The symptoms were alleviated following symptomatic treatment. After discharge, severe diarrhea recurred when the patient was readministered with semaglutide injection (0.5 mg). The symptoms abated after discontinuation of medication. Conclusion Clinicians should initiate semaglutide injection at a low dose as instructed. Particular attention should be paid to such adverse reactions as diarrhea induced by semaglutide injection. Prompt interventions are warranted once such adverse events occur.

Key words: Semaglutide, Injection, Severe, Diarrhea, Anxiety, Adverse Drug Reactions

CLC Number:

R977
R994.11

WEI Jinfei, JI Liwei. One Case of Severe Diarrhea Caused by Semaglutide Injection[J]. Chinese Journal of Pharmacovigilance, 2025, 22(10): 1171-1173.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240655

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I10/1171

References

[1] Chinese Diabetes Society.Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 Edition)[J]. Chinese Journal of Diabetes(中国糖尿病杂志), 2021, 13(4): 315-409.
[2] Panel of Glucagon-Like Peptide-1 Receptor Agonist for Treatment of Type 2 Diabetes in Primary Health Care. Expert Opinion on Glucagon-Like Peptide-1 Receptor Agonist for Treatment of Type 2 Diabetes in Primary Healthcare Type 2 Diabetes in Primary Health Care. Expert Opinion on Glucagon-Like Peptide-1 Receptor Agonist for Treatment of Type 2 Diabetes in Primary Healthcare[J]. Chinese Journal of Practical Internal Medicine(中国实用内科杂志), 2023, 43(1): 32-38.
[3] CDE, NMPA. Technical Review Report for Marketing Authorization Application of Semaglutide Injection(JXSS2000006-07)[EB/OL].(2021-11-23)[2025-05-28]. https://www.cde.org.cn/main/xxgk/postmarketpage?acceptidCODE=a719739a4b7c6d7bc7b16a2fd6dd2a20.
[4] LIU LL, JIA C, CHEN J, et al.Association between Different GLP-1 Receptor Agonists and Gastrointestinal Adverse Reactions: a Real-World Disproportionality Study Based on FDA Adverse Event Reporting System Database[J]. Frontiers in Endocrinology, 2022, 47(Suppl 1): 1-10.
[5] ZHAO YR, FANG ZW, ZHANG L, et al.Clinical Trial of Semaglutide in Adults Based on the FAERS Database[J]. Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2024, 40(2): 264-268.
[6] QIN GL, ZHOU MZ, JI SS, et al.One Case of Acute Constipation Induced by Semaglutide Injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(7): 833-835.
[7] PATEL F, GAN A, CHANG K, et al.Acute Pancreatitis in a Patient Taking Semaglutide[J]. Cureus, 2023, 15(8): e43773.
[8] CHAUDHRY A, GABRIEL B, NOOR J, et al.Tendency of Semaglutide to Induce Gastroparesis: a Case Report[J]. Cureus, 2024, 16(1): e52564.
[9] AGRA DE MELO JUNIOR C, GOMES JÚNIOR NE, DA SILVA RIBEIRO-SOUSA MA, et al. Exocrine Pancreatic Insufficiency during the Use of Semaglutide: a Case Report[J]. Cureus, 2024, 16(3): e55549.
[10] MAWARDI HH, ALMAZROOA SA, DAKHIL SA, et al.Semaglutide-Associated Hyposalivation: a Report of Case Series[J]. Medicine, 2023, 102(52): e36730.
[11] CDR, NMPA.Guideline for Collection and Reporting of Individual Case Safety Reports (ICSRs) for Adverse Drug Reactions[EB/OL]. [2024-08-10].https://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_zdyz/202009/t20200924_47831.html.
[12] BARABOI ED, ST-PIERR DH, SHOONER J, et al.Brain Activation Following Peripheral Administration of the GLP-1 Receptor Agonist Exendin-4[J]. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, 2011, 301(4): R1011-R1024.
[13] WONG CK, YUSTA B, KOEHLER JA, et al.Divergent Roles for the Gut Intraepithelial Lymphocyte GLP-1 Receptor in Control of Metabolism, Microbiota, and T Cell-Induced Inflammation[J]. Cell Metabolism, 2022, 34(10): 1514-1531.
[14] American Diabetes Association. American Diabetes Association.Standards of Care in Diabetes-2024 Diabetes[J]. Care, 2024, 47(Suppl 1): 1-321.
[15] Chinese Diabetes Society, National Office for Primary Diabetes Care. National Guidelines for the Prevention and Control of Diabetes in Primary Care (2022 edition)[J]. Chinese Journal of Internal Medicine, 2022, 61(3): 249-262.
[16] National Center of Gerontology, Chinese Society of Geriatrics, Diabetes Professional Committee of Chinese Aging Well Association. Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 edition)[J]. Chinese Journal of Diabetes Mellitus(中华糖尿病杂志), 2021, 13(1): 1-33.
[17] ZENG YT, WANG Y, ZHANG HL.A Joint Expert Consensus of Clinicians and Pharmacists on Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs)[J]. Pharmacy Today(今日药学), 2024, 34(10): 721-735.
[18] Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of Gastroenterology, et al. Guideline for Primary Care of Chronic Constipation(2019 edition)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2020, 19(11): 983-989.